Pancreatic cancer is a highly lethal disease due to its late presentation and its innate resistance to treatment. Although much research has been conducted in order to discover and develop new therapeutic targets to combat this disease, the survival gains for patients have been modest. This review aims to synopsize the current literature which has framed the approach to first and second line therapy of advanced disease. We look at the evolution of targeted therapies and briefly discuss current trials evaluating the role of immunotherapy. Finally, we cover the future of pancreatic cancer, in particular the essential role that predictive and prognostic biomarkers need to take in order to change the way we approach clinical trial design and management of patients.
|Number of pages||6|
|Publication status||Published - 1 Mar 2016|